Lieff, Cabraser, Heimann & Bernstein, LLP Announces Class Action Lawsuits on Behalf of Elan Corporation, plc Investors Against S.A.C. Capital Advisors, LP and Its Affiliates
SAN FRANCISCO--(BUSINESS WIRE)-- The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action lawsuits have been brought on behalf of all persons who purchased or otherwise acquired the American Depositary Shares ("ADRs"), call options, and/or sold the put options of Elan Corporation, plc ("Elan") (NYS: ELN) between July 21, 2008 and 4:00 pm EDT on July 29, 2008 ("Class Period"). If you purchased or otherwise acquired the ADRs, call options, and/or sold the put options of Elan during the Class Period, you may move the Court for appointment as lead plaintiff by no later than February 19, 2013. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.
Background on the Securities Class Litigation
The actions allege that, during the Class Period, S.A.C. Capital Advisors, L.P. ("SAC Capital"), CR Intrinsic Investors ("CR Intrinsic"), a wholly-owned subsidiary of SAC Capital, and other related parties, including SAC Capital founder and CEO, Steven Cohen, engaged in illegal insider trading in violation of the Securities Exchange Act of 1934 by selling Elan ADRs and trading options prior to the disclosure of adverse clinical trial results for an Alzheimer's disease drug that was central to Elan's drug development efforts. Defendants received over $220 million in illegal profits and avoided significant losses by trading on material non-public information.
According to the complaints, a portfolio manager at CR Intrinsic, Mathew Martoma, received inside information from the medical doctor who chaired the drug's safety monitoring committee, Sidney Gilman. The complaints further allege that Martoma subsequently shared this information with Cohen, and over the following seven trading days, SAC Capital and Martoma liquidated their entire holdings of Elan ADRs, worth over $365 million, and acquired short positions in Elan, and eventually sold over $500 million in Elan securities before the disclosure of adverse results from the clinical trial.
On July 29, 2008, after the close of trading, the adverse results of the clinical trial were publicly disclosed. Upon this news, Elan's ADRs declined 41.8% the next day.
According to the complaint, Martoma is presently the subject of a criminal prosecution for his alleged role in the insider trading of Elan securities. Gilman has settled civil charges brought by the Securities and Exchange Commission, agreed to disgorge more than $200,000, and entered into a non-prosecution agreement with the U.S. Attorney's office for his role in the illegal scheme.
Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.
Since 2003, the National Law Journal has selected Lieff Cabraser as one of the top plaintiffs' law firms in the nation. In compiling the list, the National Law Journal examined recent verdicts and settlements in addition to overall track records. Lieff Cabraser is one of only two plaintiffs' law firms in the United States to receive this honor for the last ten consecutive years.
For more information about Lieff Cabraser and the firm's representation of investors, please visit http://www.lieffcabraser.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
for Media Inquiries Only:
Lieff Cabraser Heimann & Bernstein, LLP
Sharon M. Lee, 800-541-7358
KEYWORDS: United States North America California
The article Lieff, Cabraser, Heimann & Bernstein, LLP Announces Class Action Lawsuits on Behalf of Elan Corporation, plc Investors Against S.A.C. Capital Advisors, LP and Its Affiliates originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.